Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

• Status: Completed
• Trial end date: 2003-12-17

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 in healthy male subjects.

• Phase: Phase 1

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Long-Acting